1354623-45-2

Upstream product

• 817637-39-1 (E)-methyl 3-(4-methoxybenzyloxy)acrylate 
• 768401-29-2 tert-butyl (2S,4R)-4-hydroxycarbonyl-2-(tert-butyl)-1,3-oxazolane-3-carboxylate 
• 380429-42-5 tert-butyl (2S,4R)-4-methoxycarbonyl-2-(tert-butyl)-1,3-oxazolane-3-carboxylate 
• 257291-68-2 methyl (R)-2-tert-butyloxazolidine-4-carboxylate 
• 105-13-5 4-Methoxybenzyl alcohol 
• 24424-99-5 di-tert-butyl dicarbonate 
• 4480-47-1 t-butylglyoxal 
• 1354623-29-2 3-tert-butyl 4-((E)-3-(4-methoxybenzyloxy)allyl) (2S,4R)-2-tert-butyloxazolidine-3,4-dicarboxylate 
• 1133378-77-4 (E)-3-((4-methoxybenzyl)oxy)prop-2-en-1-ol 

Downstream Products

• 1354623-48-5 4-benzyl 3-tert-butyl (2S,4S)-2-tert-butyl-4-((R)-1-hydroxyallyl)oxazolidine-3,4-dicarboxylate 
• 1354623-50-9 4-benzyl 3-tert-butyl (2S,4S)-2-tert-butyl-4-((R,E)-1-hydroxy-12-oxooctadec-2-enyl)oxazolidine-3,4-dicarboxylate 

Relevant academic research and scientific papers

Remote stereocontrol in [3,3]-sigmatropic rearrangements: Application to the total synthesis of the immunosuppressant mycestericin G

The Ireland - Claisen [3,3]-sigmatropic rearrangement has been used to access biologically important β,β′-dihydroxy α-amino acids. The rearrangement reported is highly stereoselective and offers excellent levels of remote stereocontrol. This strategy has been used to synthesize the natural immunosuppressant mycestericin G and ent-mycestericin G, allowing for a revision of absolute configuration of this natural product.